confirms in Medical Technology

Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients

Suggests additional training to help brain adapt more fully and further enhance benefits BOSTON, May 19 /PRNewswire-USNewswire/ -- In a study of specially designed peripheral prism glasses for hemianopia patients (blinded in half the visual field in both eyes), scientists found that two-thir...

CVS Caremark Data Confirms Improved Outcomes for Women with Osteoporosis Who are Adherent to Therapy

Non-adherent women up to six times more likely to experience a fracture WOONSOCKET, R.I., May 11 /PRNewswire/ -- Data released today by CVS Caremark (NYSE: CVS ) indicates that 87 percent of women 18 years and older with osteoporosis, who were taking a drug therapy to treat the disease, di...

Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel

ALLEGAN, Mich., March 17 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO ; TASE) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a generic version of Evoclin(R) Foam 1%. The Company bel...

New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions

Study was conducted with 274 adults with intellectual disabilities currently receiving funding from a state developmental disability agency WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- The Supports Intensity Scale (SIS) assessment tool can effectively predict funding for people with intelle...

Sosei Confirms the Safety of SD118 in Two Phase I Trials

TOKYO, December 8 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the successful results of two Phase I trials for its collaborative project on SD118, a compound in development for the treatment of neuropathic pain....

National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon

Study evaluates the efficacy of new device for detecting polyps that can be missed during colonoscopy ORLANDO, Fla., Oct. 7 /PRNewswire/ -- At the American College of Gastroenterology Annual Scientific Meeting in Orlando (ACG 2008), renowned gastroenterologist Douglas K. Re...

Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO ), a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new dru...

Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A

BRISBANE, Australia, July 22 /PRNewswire-FirstCall/ -- Following a thorough review that concluded late yesterday, the Board of Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that it had discontinued the PI-88 phase 3 study in liver cancer. Progen confirmed its strategi...

New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients

BASEL, Switzerland, June 11 /PRNewswire-FirstCall/ -- - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer pa...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

SAN FRANCISCO, June 8 /PRNewswire-FirstCall/ -- A head-to-head study announced today at the American Diabetes Association (ADA) meeting demonstrated that Levemir(R) (insulin detemir [rDNA origin] injection) can be used once-daily and had a comparable blood glucose response to insulin glargine ...

University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients

New data presented at annual American Transplant Congress in Toronto MIAMI, June 2 /PRNewswire/ -- Manuel R. Carreno, MD, and colleagues in the Departments of Surgery and Pathology at the University of Miami - Lawrence Miller School of Medicine have corroborated the value of monitoring cell-...

Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer

- Data From Pivotal Phase III AVADO Study Presented at ASCO for the First Time BASEL, Switzerland, May 31 /PRNewswire/ -- Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease getting worse ("pro...

AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients

-Specific biomarkers for molecular tumor grade and endocrine benefit offer better prediction of individual patient outcome- SAN DIEGO, May 13 /PRNewswire/ -- AviaraDx, Inc. today announced the publication of an article describing the discovery, development and validation of a new mol...

New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen

100% of Insulin Doses Administered Were Delivered Within Pre-Determined Guidelines and Standard Dosing Limitations BRIDGEWATER, N.J., May 5 /PRNewswire-FirstCall/ -- A new study examining the dose accuracy of the SoloSTAR(R) disposable insulin pen, prefilled with Lantus(R) (insul...

Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer

Second Phase Opens With Higher Dose Regimens SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no majo...

FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects

HENDERSON, Nev., Nov. 20 /PRNewswire/ -- FDA spokesman, Brad Swezey, affirmed to the Wall Street Journal (WSJ) yesterday that the FDA had not received any reports of patient injuries or adverse effects related to use of the eyelash product the agency seized last Friday. According to its Novem...

New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models

-- Data Presented at Anti-Angiogenesis Conference Shows R84, the Selective Human Anti-VEGF Antibody Developed by Peregrine in Association with Affitech, Is Equivalent to Avastin in Inhibiting Growth of Established Tumors in a Preclinical Breast Cancer Model -- -- R84 Is Being ...

Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients

MINNEAPOLIS, Nov. 9 /PRNewswire-USNewswire/ -- This week, Dr. Fouad Bachour, MD, FACC, director of interventional cardiology at Hennepin County Medical Center, presented results of a study at the American Heart Association's Scientific Sessions ( http://www.sessionsdailynews.com/tuesday.pdf ) ...

IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients

IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI ) today announced the presentation of updated survival data from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The trial was part of a National Cancer Institute (NCI) funded cooperative group study...

Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006

New software will provide first real-time analysis of such infectious-disease outbreaks SEATTLE, Aug. 28 /PRNewswire/ -- In the first systematic, statistical analysis of its kind, infectious-disease-modeling experts at Fred Hutchinson Cancer Research Center confirm ...

New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis

Majority of Infants Infected by Members of Their Own Household SWIFTWATER, Pa., March 27, 2007 /PRNewswire/ -- A new study released today in the April issue of The Pediatric Infectious Disease Journal about the transmission of pertussis -- commonly known as whooping cough -- found that household m...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin® (homoharringtonine). The paper "Targeted therapy and the T315I mutation in ...

Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--May 21, 2007 - ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin(R) (homoharringtonine). The paper "Targeted therapy and the T315I mutation...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Franchise SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene Corporation announced its plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory disea...

New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients

Aggrenox® (Asasantin® Retard) considered by many as first-line in secondary stroke prevention INGELHEIM, Germany, 31 May 2007 - New data presented today at the 16th European Stroke Conference in Glasgow confirm that therapy with dipyridamole plus ASA (extended-release dipyridamole plus...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

Second Multinational Phase III Study Provides Further Evidence of the Significant Role of IL-6 Receptor Inhibition in the Treatment of Rheumatoid Arthritis BASEL, Switzerland, June 6, 2007-Roche announced today that Toward (1), the second multinational phase III Actemra (tocilizumab) study, succes...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced that a study published recently in the Proceedings of the Nation...

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces today that it has received very positive results in the dose finding part of its phase IIb/III clinical trial started in autumn 2006. BF-200 ALA, a gel that combines the active substance 5-aminolevulinic acid (ALA) with the nanoemulsion BF-...

Regular Yoga Practice Is Associated With Mindful Eating

...sical activity of yoga practice itself. The follow-up study, published in the August issue of the Journal of the American Dietetic Association, confirms their initial hunch. "In our earlier study, we found that middle-age people who practice yoga gained less weight over a 10-year period than tho...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

...ins, Dove developed its latest liquid cleansing technology called NutriumMoisture. Research published in the June 2009 issue of Cosmetic Dermatology confirms NutriumMoisture is clinically proven to preserve both skin's natural proteins and lipids while significantly reducing dryness and improving moisturiz...

New Review on PROSTVAC(TM) Published by Key Investigators From NCI

...nmark, July 1 /PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far. Quote from the ar...

Brain Fitness Makes Boomers Age Younger

...dy was published in the April issue of the Journal of the American Geriatrics Society, a journal for doctors who are board certified in Geriatrics. It confirms earlier studies showing similar effects and imaging research showing enhanced brain activity. Posit Science Posit Science is the leading prov...

Clinical and Histopathological Results Using Pollogen's TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy

...swire/ -- A recent clinical study using Pollogen's regen(TM) device- the latest aesthetic solution powered by 3rd generation TriPollar(TM) technology, confirms the safety and efficacy of TriPollar(TM) technology in reducing fat and collagen remodeling. The peer reviewed paper entitled "Clinical and histopatho...

Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment

...losure of the greater saphenous vein," said Jose I. Almeida, M.D., lead author of the study and Medical Director of Miami Vein Center. "The study confirms what many of us who have used both laser and radiofrequency devices have felt subjectively - that there is significantly enhanced patient comfort with...

Single Port Surgeries Now Performed at University Medical Center at Princeton

...on also means less post-operative pain and slightly reduced risk of infection than a recovery from multiple incisions. Dr. Davison's experience confirms these benefits. He estimates that 75 percent of his single port patients are going home directly from the recovery room, where previously more than h...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... Data Presented at Meeting of European Hematology Association confirms High Response Rate and Durability of Remissions BERLIN, June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical co...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...nd death. Less than 25 percent of CLL patients who are resistant to current treatments respond to available therapies. "The positive vote by ODAC confirms that ofatumumab may offer a new treatment option for patients who have received prior therapies with this type of CLL," said Lisa N. Drakeman, Ph.D., ...

New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease

... Study Presented at the American Thoracic Society by Researchers at The Children's Hospital of Philadelphia confirms Accuracy and Clinical Value of Noninvasive SpCO(R) and SpMet(R) IRVINE, Calif., May 19 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

...apies when taken over a 28-day period, according to preliminary data derived from the company's Phase IIa clinical trial. "This preliminary data confirms that a PPAR-sparing thiazolidinedione (TZD) can improve insulin sensitivity and lower glucose similar to a traditional TZD," said Dr. Jerry Colca, p...

New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug

...ven the large number of patients affected," said Dr. Robert Epstein, Medco's chief medical officer and one of the study researchers. "While this study confirms prior research in this area, it brings us a step further in our understanding by showing that this is a problem associated with each of the four most ...